PENTETATE ZINC TRISODIUM

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H18N3O10.3Na.Zn
Molecular Weight	522.685
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].[Na+].[Zn++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O

InChI

InChIKey=HVASDHJNLYRZEA-UHFFFAOYSA-I

InChI=1S/C14H23N3O10.3Na.Zn/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;;;;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);;;;/q;3*+1;+2/p-5

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C14H18N3O10
Molecular Weight	388.3068
Charge	-5
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Zn
Molecular Weight	65.409
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18830865 | https://www.truthinaging.com/ingredients/pentasodium-pentetatehttp://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021749lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.federalregister.gov/articles/2011/08/19/2011-21227/determination-that-pentetate-calcium-trisodium-trisodium-calcium-diethylenetriaminepentaacetate

Pentetate calcium trisodium is also known as trisodium calcium diethylenetriaminepentaacetate and is commonly referred to as Ca-DTPA is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. It is a white, water-soluble solid. It has a molecular formula of Na3CaC14H18N3O10 and a molecular weight of 497.4 Daltons. Ca-DTPA is supplied as a clear, colorless, hyperosmolar (1260 mOsmol/kg) solution in a colorless ampoule containing 5 mL. The ampoule contents are sterile, non-pyrogenic and suitable for intravenous administration. Each mL of solution contains the equivalent of 200 mg pentetate calcium trisodium (obtained from 158.17 mg pentetic acid, 40.24 mg calcium carbonate and NaOH) in water for injection, USP. The pH of the solution is adjusted with NaOH and is between 7.3 - 8.3. Ca-DTPA forms stable chelates with metal ions by exchanging calcium for a metal of greater binding capacity. The radioactive chelates are then excreted by glomerular filtration into the urine. In animal studies, Ca-DTPA forms less stable chelates with uranium and neptunium in vivo resulting in the deposition of these elements in tissues including the bone. The Food and Drug Administration (FDA) has determined that PENTETATE CALCIUM TRISODIUM (trisodium calcium diethylenetriaminepentaacetate (Ca-DTPA)) solution for intravenous or inhalation administration, equivalent to (EQ) 1 gram (g) base/5 milliliters (mL) (EQ 200 milligrams (mg) base/mL) was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for PENTETATE CALCIUM TRISODIUM (Ca-DTPA) solution for intravenous or inhalation administration (EQ 1 g base/5 mL (EQ 200 mg base/mL)), if all other legal and regulatory requirements are met. Ca-DTPA treatments are not expected to be effective for uranium and neptunium. Radioactive iodine is not bound by DTPA

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Metallic ions 7 Target ID: Metallic ions Sources: https://www.ncbi.nlm.nih.gov/pubmed/18830865	Chelating Agent 142
Radioactive metals 7 Target ID: CHEMBL2366037 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021749lbl.pdf	Chelating Agent 142

Conditions

Condition	Modality	Highest Phase	Product
Acne 98 Sources: https://www.drugs.com/otc/110273/dermaklear-akne-treatment-with-sulfur.html	Inactive ingredient	Approved 8429	DermaKlear Akne Treatment with Sulfur Approved Use Uses for the treatment of acne. Dries acne blemishes and allows skin to heal. Helps prevent new acne blemishes from forming. Launch Date 1940
Contamination with plutonium, americium, or curium 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021749lbl.pdf	Diagnostic	Withdrawn	PENTETATE CALCIUM TRISODIUM Approved Use Ca-DTPA is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. Launch Date 2004
Internal contamination with plutonium, americium, or curium 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021751s008lbl.pdf	Palliative	Approved 8429	PENTETATE ZINC TRISODIUM Approved Use Pentetate zinc trisodium injection is a radiomitigation chelator indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. Launch Date 2004

C_max

Value	Dose	Co-administered	Analyte	Population
1.6 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16257469/	29.4 μmol/kg single, intravenous dose: 29.4 μmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:		PENTETIC ACID plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
0.007 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16257469/	29.4 μmol/kg single, intravenous dose: 29.4 μmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:		PENTETIC ACID plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.53 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16257469/	29.4 μmol/kg single, intravenous dose: 29.4 μmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:		PENTETIC ACID plasma	Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.5 g 1 times / day multiple, subcutaneous (starting) Dose: 0.5 g, 1 times / day Route: subcutaneous Route: multiple Dose: 0.5 g, 1 times / day Co-administed with:: Zinc sulphate(200 mg two to five times daily) Sources: https://pubmed.ncbi.nlm.nih.gov/2923478	unhealthy, 5-20 years) n = 5 Health Status: unhealthy Condition: homozygous beta thalassaemia Age Group: 5-20 years) Sex: M+F Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/2923478	Sources: https://pubmed.ncbi.nlm.nih.gov/2923478
4 g 1 times / day multiple, intramuscular Overdose Dose: 4 g, 1 times / day Route: intramuscular Route: multiple Dose: 4 g, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf	Other AEs: Hemochromatosis... Other AEs: Hemochromatosis (grade 5, 3 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf

AEs

AE	Significance	Dose	Population
Hemochromatosis	grade 5, 3 patients	4 g 1 times / day multiple, intramuscular Overdose Dose: 4 g, 1 times / day Route: intramuscular Route: multiple Dose: 4 g, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:35739	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:35739
ChemicalBook	CB5303977	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5303977
MolPort	MolPort-002-324-582	https://www.molport.com/shop/molecule-link/MolPort-002-324-582
ZINC	ZINC000019419017	http://zinc15.docking.org/substances/ZINC000019419017
eMolecules	497513	https://www.emolecules.com/cgi-bin/more?vid=497513

PubMed

Title	Date	PubMed
Role of S-adenosyl-L-methionine in potentiating cadmium mobilization by diethylenetriamine penta acetic acid in mice.	2001	11258544
Comparison of written reports of mammography, sonography and magnetic resonance mammography for preoperative evaluation of breast lesions, with special emphasis on magnetic resonance mammography.	2001	11250746
Evaluation of copper availability to plants in copper-contaminated vineyard soils.	2001	11202733
Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results.	2001 Apr	11306390
In vitro evaluation of intravascular stent artifacts in three-dimensional MR angiography.	2001 Apr	11283419
Prediction rule for characterization of hepatic lesions revealed on MR imaging: estimation of malignancy.	2001 Apr	11264070
A cream containing the chelator DTPA (diethylenetriaminepenta-acetic acid) can prevent contact allergic reactions to metals.	2001 Apr	11260238
Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.	2001 Apr 1	11306478
Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging.	2001 Apr 23	11304163
Bilaminar pattern of tibial condyle cartilage layer on the fat-suppressed 3D gradient echo images: artifact or structural and biochemical difference in composition of cartilage?	2001 Feb	11358656
Development of an in vitro model for assessing the in vivo stability of lanthanide chelates.	2001 Feb	11295425
Different chelators and different peptides together influence the in vitro and mouse in vivo properties of 99Tcm.	2001 Feb	11258408
Effect of iron and ascorbate on cyclosporine-induced oxidative damage of kidney mitochondria and microsomes.	2001 Feb	11243718
Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage.	2001 Feb	11224754
64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.	2001 Feb	11216519
[The scintigraphy of somatostatin receptors in the carcinoid tumor].	2001 Feb	11181324
The importance of ligand speciation in environmental research: a case study.	2001 Feb 21	11286213
Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating dtpa tails and of their zinc complexes with powerful topical antiglaucoma properties.	2001 Feb 26	11229775
Images in clinical medicine. Captopril-augmented renal scan.	2001 Feb 8	11172180
Acute and subacute physiological and histological studies of the central nervous system after intrathecal gadolinium injection in the anesthetized rat.	2001 Jan	11176259
Surveillance of peripheral arterial bypass grafts with three-dimensional MR angiography: comparison with digital subtraction angiography.	2001 Jan	11133569
Chelated metal ions for therapeutic and diagnostic applications.	2001 Jul	11444098
Detection of cerebrospinal fluid leak by dual-isotope spect with In-111 DTPA and Tc-99m HMDP.	2001 Jul	11416747
Lanthanide chemistry with (bis[[bis(carboxymethyl)amino]methyl]phosphinate: what does an extra phosphinate group do to EDTA?	2001 Jul 16	11442371
Gastric emptying is accelerated in obese type 2 diabetic patients without autonomic neuropathy.	2001 Jun	11431601
Scintigraphy and Doppler ultrasonography for the evaluation of obstructive urinary calculi.	2001 Jun	11378662
Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.	2001 Jun 1	11389078
The kinetics and mechanisms of the reactions of aluminium(III) with gallic acid, gallic acid methyl ester and adrenaline.	2001 Mar	11330467
Tc-99m DTPA renography in patients with collagen disease.	2001 Mar	11245107
Contrast-enhanced MR imaging of coronary arteries: comparison of intra- and extravascular contrast agents in swine.	2001 Mar	11230638
Adrenal masses: quantification of fat content with double-echo chemical shift in-phase and opposed-phase FLASH MR images for differentiation of adrenal adenomas.	2001 Mar	11230633
Clinical relevance of lower Hib response in DTPa-based combination vaccines.	2001 Mar 21	11257348
Synthesis, characterization, and relaxivity of two linear Gd(DTPA)-polymer conjugates.	2001 Mar-Apr	11312677
Rapid imaging of human melanoma xenografts using an scFv fragment of the human monoclonal antibody H11 labelled with 111In.	2001 May	11388583
Dysprosium-bearing red cells as potential transverse relaxation agents for MRI.	2001 May	11323820
Three-dimensional contrast-enhanced MR angiography of endovascular covered stents in patients with peripheral arterial occlusive disease.	2001 May	11312198
Reactive oxygen species involved in trichosanthin-induced apoptosis of human choriocarcinoma cells.	2001 May 1	11311127
Negatively charged polymers protect antinuclear antibody against inactivation by acylating agents.	2001 May 15	11355857
Quantitative assays of the amount of diethylenetriaminepentaacetic acid conjugated to water-soluble polymers using isothermal titration calorimetry and colorimetry.	2001 May-Jun	11353534
Final report on the safety assessment of pentasodium pentetate and pentetic acid as used in cosmetics.	2008	18830865

Patents

Sample Use Guides

In Vivo Use Guide

Rats: The acute oral LD(50) of Pentasodium Pentetate in rats was > 5 g/kg. The acute dermal LD(50) of Pentapotassium Pentetate using rats was reported to be > 2 g/kg. The intraperitonal LD(50) of Pentetic Acid was reported to be 585 mg/kg.

Route of Administration: Other

In Vitro Use Guide

Approximately 0.1 ml of solution of Ca-DTPA (pentetate calcium trisodium) was added to the test cultures (human lymphocytes) at 3 different concentrations: 0.77, 0.077, and 0.0077 mg/ml, resulting in a final concentration in the culture medium of 13.51, 1.351, and 0.135 ug/ml, respectively.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:40:15 GMT 2023` Edited by `admin` on `Fri Dec 15 15:40:15 GMT 2023`
Record UNII	NXU65IC8PG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PENTETATE ZINC TRISODIUM

Common Name

English

TRISODIUM (N,N-BIS(2-(BIS(CARBOXYLATOMETHYL)AMINO)ETHYL)GLYCINATO(5-))ZINCATE(3-)

Common Name

English

PENTETATE ZINC TRISODIUM [VANDF]

Common Name

English

TRISODIUM ZINC DTPA

Common Name

English

PENTETATE ZINC TRISODIUM [HSDB]

Common Name

English

DIETHYLENETRIAMINE PENTACETIC ACID TRISODIUM ZINC SALT

Common Name

English

PENTETATE ZINC TRISODIUM [ORANGE BOOK]

Common Name

English

DIETHYLENETRIAMINEPENTAACETIC ACID, ZINC TRISODIUM SALT

Common Name

English

ZINC TRISODIUM PENTETATE

Common Name

English

TRISODIUM ZINC DIETHYLENETRIAMINEPENTAACETATE

Common Name

English

ZINCATE(3-), (N,N-BIS(2-(BIS(CARBOXYMETHYL)AMINO)ETHYL)GLYCINATO(5-))-, TRISODIUM

Common Name

English

Pentetate zinc trisodium [WHO-DD]

Common Name

English

ZINC TRISODIUM PENTETATE [MART.]

Common Name

English

PENTETATE ZINC TRISODIUM [JAN]

Common Name

English

KELAZIN

Brand Name

English

ZINC-DTPA

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C62357